Exciting new data show that adjuvant targeted agent olaparib after chemotherapy can cut the risk of BRCA-mutated breast cancer returning or spreading in women
Following more than two decades of extraordinary developments and advancements in cancer research – from molecular mechanisms to clinical care to new enabling technologies, we are better equipped than ever before to deliver a much more personalised, targeted form of cancer treatment and care.
Expert says widely applicable predictive testing is needed to improve prevention, diagnosis and treatment
Although knowledge on pathogenic germline variants has improved over the years, researchers are hunting for new genetic causes of cancer to better identify families at higher risk to develop the disease
Tumour evolution is one of the primary reasons for resistance to treatment and researchers are now learning how to use it to lead tumours down a dead end
How ESMO is transforming the challenges from the COVID-19 pandemic into opportunities to re-shape the future of the oncology community
As the complexity of the cancer landscape increases, miscommunication and misunderstanding emerge as major obstacles to patient self-determination
Efficacy of targeted therapies has enabled unprecedented survival gains in the last few years, but Prof. Jean-Charles Soria believes overcoming drug resistance is likely to be a local battle fought in the tumour microenvironment
Despite early promises, advances are needed in targeting tumour-specific epitopes, overcoming the tumour microenvironment, and automating CAR-T production, explains Prof. Ulrike Köhl
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.